Drug Discovery and Development

He is a medical-physical scientist and an educator. He is the current President/CEO and Institute Professor at the International Institute of Medicine & Science with a previous appointment as Executive Vice President/Chief Operating Officer and Professor at the Weil Institute of Critical Care Medicine, California, U.S.A. He was formerly Professor of Radiology, Radiological Sciences, Radiation Oncology, Critical Care Medicine and Physics at several U.S. and European Universities. Earlier, he was Deputy Director (Western Region) of the U.S. Department of Veterans Affairs (Office of Research Oversight). At the Loma Linda Veterans Affairs Medical Center, he was Scientific Director of Radiology, Director of the Magnetic Resonance Imaging Center and, for a time, Acting Chair of Radiology. Previously, he was also Director of the Division of Biomedical and Biobehavioral Research at the University of California at Los Angeles/Drew University of Medicine and Science and an Advisor to the U.S. National Academy of Sciences, National Research Council, for postdoctoral programs tenable at the California Institute of Technology. He is Health Advisor to the American Heart & Stroke Association, Coachella Valley Division, California. He is a frequent Keynote Speaker and International Organizing Committee Member of several international scientific conferences. He has lectured extensively in the U.S., Europe, Asia and Africa. He has published ~ 425 scholarly scientific publications and books. He is also Editor-in-Chief, Honorable Editor or Editor of 62 medical/scientific Journals to which he contributes regularly. Dr. Fymat is a Board member of several institutions, a professional member of the New York Academy of Sciences and a reviewer for the prestigious UNESCO Newton Prize, United Kingdom National Commission for UNESCO. His current research interests are focused on neurodegenerative diseases (Alzheimer, Parkinson, epilepsy, dementias and others), oncology, molecular/precision/personalized medicine, and nanomedicine and nanobiotechnology.

His current research interests lie at the interface between science and medicine, particularly molecular/personal/precision medicine, nanomedicine, human genetics/epigenetics/ecogenetics, and pharmacogenomics. His most recent publications deal with magnetic resonance Imaging with nanocontrasting materials, nanotechnology and cancer, nanochemotherapy, nanoneurology, natural and synthetic immunotherapy, drug delivery including across the brain protective barriers, and drug manufacturing in Africa.

Yavuz is the chairman of Istanbul Consulting Group. ICG(Istanbul Consulting Group) was founded in 2013 and provided guidance to the Turkish ministry of health as part of a World Bank project. Yavuz is currently the Co-Founder of BioCube İstanbul Bioentrepreneurship & Innovation Center and Corporate Communication Director of Sumitomo Group/ Expel İlaç Archem Diagnostics Ended and Diagen. He previously managed the largest distributor of Siemens Healthcare in Turkey managing 250 employees and director of Avcılar Hospital R&D Center, Chief Medical Officer of Lifematrix GmbH. Previously he worked as the Market Access & Health Policy Director for AIFD in Turkey. Yavuz previously worked as the Vice President of Ipsen pharmaceutical and Director of Teva pharmaceutical in the USA managing large clinical trials as well as Investigator Initiated Trials and developing relationships with Key Opinion Leaders. Previously, Yavuz was the Associate Director at KV Pharmaceuticals and Director in Clinical Development department at Forest Laboratories. Yavuz earned his MD from the Faculty of Medicine, the University of Ankara in Ankara, Turkey. He completed a clinical internship at Baylor College of Medicine in Houston, followed by continued research training at The University of Texas MD Anderson Cancer Center in Houston. He recently completed his Executive MBA at the Olin Business School at Washington University in St. Louis.

Neurology, Pulmonary Critical Care, Rheumatology, Oncology and related therapeutic areas within academics and industry. regulatory processes, identifying and addressing risk management issues throughout the lifecycle, presentation development to large payers, safety monitoring, designing and conducting clinical trials.

George Perry (born April 12, 1953 in Lompoc, California) is a neuroscientist recognized in the field of Alzheimer's disease research particularly for his work in oxidative stress. Dr. Perry has studied at many universities and holds multiple degrees including a Bachelor of Arts degree in Zoology from the University of California Santa Barbara and a PhD in Marine Biology from the University of California at San Diego. He is distinguished as one of the top Alzheimer’s disease researcherswith over 1000 publications, more than 60,000 citations, one of the top 100 most-cited scientists in Neuroscience & Behavior and one of the top 25 scientists in free radical research. Dr. Perry is a Semmes Foundation Distinguished chair in Neurobiology and is an active participant in many other scientific associations. In addition, Perry is an Editor of numerous scientific journals including Journal of Alzheimer’s Diseasewhich he founded in 1998. Today, Perry continues his love for research while working as Dean of the College of Sciences at The University of Texas at San Antonio.

role of redox active metals in mediating prooxidant and antioxidant properties

Professor C.H. Cho received his undergraduate and master training in Taiwan and USA. He graduated with a PhD in Pharmacology from the University of Hong Kong (HKU) in 1978. He went through his postdoctoral training in Canada and started his first faculty position in the National Yang Ming Medical College and Veterans General Hospital Taipei in 1981 as associate professor and investigator, respectively in Taiwan. He went back to HKU in 1984 as lecturer in the Department of Pharmacology and became Chair Professor of Pharmacology in 2000. Later in his academic career, Prof. Cho joined the Chinese University of Hong Kong (CUHK) in 2007 as Chairman and Professor of Pharmacology in the Department of Pharmacology. He has been the Research Professor and Associate Director of the School of Biomedical Sciences, Faculty of Medicine in CUHK. He becomes Emeritus Professor in the same university in 2016. Professionally he was President (2006-2010) and Chair of Presidential Council (2012-2015) of the Gastrointestinal Pharmacology Section of the International Union of Basic and Clinical Pharmacology and also council members in a number of professional bodies in ulcer research and gastrointestinal pharmacology. Prof. Cho has been the Visiting and Honorary Professors in the University of Hong Kong, Peking University, Fudan University, Zhejiang University, Virginia Tech, University of Maryland, and University of California and also Distinguished Professor in the Southwest Medical University. His current research interests focus on drug development for inflammation and cancers in the gastrointestinal tract. He publishes over 370 peer-reviewed articles and 60 reviews in journals and 18 book chapters. He is also the editor of eight books in gastrointestinal ulcer and cancer. He holds 2 patents concerning drug treatment for gastrointestinal disorders in CUHK. Professor Cho has served as the editorial board member, associate editor and editor in more than 55 journals in the fields of Gastroenterology and Pharmacology.

drug development for inflammation and cancers in the gastrointestinal tract

Professor Adrian trained at the Royal Postgraduate Medical School (Imperial College) in London, UK. At Yale University he was Director of the Gastrointestinal Surgical Research. At Creighton University he was Research Director Research in the Cancer Center. He moved to Northwestern University School of Medicine in Chicago, where he was Director of Gastrointestinal Cancer Research. In 2006, he became Professor and Chairman of the Department of Physiology, in the College of Medicine and Health Sciences UAE University. He has published more than 400 articles in peer-reviewed journals (>23,000 citations, H index 76) and 85 reviews and book chapters.

Gastrointestinal Surgical Research,Cancer Research

Dr. Yung-Chih Kuo is a professor at the Department of Chemical Engineering, National Chung Cheng University. His research interests are focused on biomaterials, drug delivery system, nanomedicine, tissue engineering (cartilage and pancreas), blood–brain barrier, cancer therapy, nerve regeneration, spinal cord injury treatment, stroke treatment, Alzheimer’s disease therapy, Parkinson’s disease therapy, biophysics, colloid and interface science. In these fields, he has authored or coauthored over 130 SCI journal papers, over 10 book chapters and patents. He is a fellow of Royal Society of Chemistry (UK), an honor member of Phi Tau Phi Society, a life member in various academic Societies including American Nano Society, European Atherosclerosis Society, European Association for Cancer Research, Society for Cardiovascular Magnetic Resonance, Asia-Pacific Chemical, Biological and Environmental Engineering Society, Asian Federation of Biotechnology, Asian Biotechnology Directory, Taiwanese Society of Biomedical Engineering, Chinese Institute of Engineers, Taiwan Institute of Chemical Engineers, Biochemical Engineering Society of Taiwan, and Taiwan Biomaterials and Controlled Release Society. He won the Best Paper Award in 2016 and 2008, Prof. Tsai-Teh Lai Award in 2015, Special and Talented Scholar Award in 2013-5, Outstanding Research Award in 2013, and Young Scholar Award in 2003. He is also an associate editor of J. Taiwan Inst. Chem. Eng. and an editorial board member in various journals, and has been invited as an organizing committee member of many international conferences, a manuscript reviewer for over 100 journals (top reviewer of the Journal of Physical Chemistry (American Chemical Society)), an external reviewer for academic awards, research grants, faculty recruitments and promotions, and financial support of hosting international symposiums, and an advisory board committeeman of international conferences and symposiums.

His research interests are focused on biomaterials, drug delivery system, nanomedicine, tissue engineering (cartilage and pancreas), blood–brain barrier, cancer therapy, nerve regeneration, spinal cord injury treatment, stroke treatment, Alzheimer’s disease therapy, Parkinson’s disease therapy, biophysics, colloid and interface science.

Since 2002, Yong Tae Kwon has been working as a faculty member of the Department of Pharmaceutical Sciences of University of Pittsburgh. In 2010, he got a dual appointment at Seoul National University College of Medicine. He is currently Director of Protein Metabolism Medical Research Center of Seoul National University. His research focuses on protein degradation in the field of biochemistry, in particular a proteolytic pathway called the N-end rule pathway. Over the course of he published search papers in many high-end journals, including Nat Cell Biology, Cell, Science, Nature Genetic, Proc Natl Acad Sci, Nat Rev Mol Cell Biol, Nat Struc Mol Biol, and Ann Rev Biochem.

His research focuses on protein degradation in the field of biochemistry, in particular a proteolytic pathway called the N-end rule pathway. Over the course of he published search papers in many high-end journals, including Nat Cell Biology, Cell, Science, Nature Genetic, Proc Natl Acad Sci, Nat Rev Mol Cell Biol, Nat Struc Mol Biol, and Ann Rev Biochem.

Professor Zvi Naor is an emeritus Professor in the Department of Biochemistry and Molecular Biology, at George S Wise Faculty of Life Sciences, Tel Aviv University, Israel. Professor Naor has published over 150 papers on the subject of GnRH receptor signaling. He is a recognized expert in the field of endocrinology, reproductive biology and signal transduction. Prof. Naor was invited to many international meetings around the world. After obtaining a PhD Degree in Biochemistry from the Weizmann Institute in of Science in Israel, he did two post-doctorate training, the first in the University of Texas Health Science Center in Dallas, TX, USA and the 2nd in the NIH, MD, USA. He then returned to Israel to the Weizmann Institute of Science and became Associated Professor in 1987. He spent 1 year in the University of Kobe, Japan for a Sabbatical working with the late Y. Nishizuka (1988). Upon returning to Israel he joined the Department of Biochemistry at Tel Aviv University, Israel where he is currently working as a Pofessor.

Professor Naor has published over 150 papers on the subject of GnRH receptor signaling. He is a recognized expert in the field of endocrinology, reproductive biology and signal transduction

Professor Zvi Naor is an emeritus Professor in the Department of Biochemistry and Molecular Biology, at George S Wise Faculty of Life Sciences, Tel Aviv University, Israel. Professor Naor has published over 150 papers on the subject of GnRH receptor signaling. He is a recognized expert in the field of endocrinology, reproductive biology and signal transduction. Prof. Naor was invited to many international meetings around the world. After obtaining a PhD Degree in Biochemistry from the Weizmann Institute in of Science in Israel, he did two post-doctorate training, the first in the University of Texas Health Science Center in Dallas, TX, USA and the 2nd in the NIH, MD, USA. He then returned to Israel to the Weizmann Institute of Science and became Associated Professor in 1987. He spent 1 year in the University of Kobe, Japan for a Sabbatical working with the late Y. Nishizuka (1988). Upon returning to Israel he joined the Department of Biochemistry at Tel Aviv University, Israel where he is currently working as a Pofessor.

Professor Naor has published over 150 papers on the subject of GnRH receptor signaling. He is a recognized expert in the field of endocrinology, reproductive biology and signal transduction

Prof.(Dr.) Shamim Ahmad is Distinguished Professor of Microbiology and Officer In-Charge at Microbiology Section , Institute of Ophthalmology ,JN Medical College ,Faculty of Medicine , Aligarh Muslim University ,Aligarh ,India being working since January,10,1983 .Beside, he has recently been working as Superintendent of Examinations of the Faculty of Medicine, AMU, Aligarh. Prof. Ahmad had has also served as Faculty on deputation from AMU Aligarh for about 5 years at Faculties of Medicine in the Department of Clinical Microbiology, Al-Arab Medical University, Libya and Department of Medical Microbiology, College of Medicine ,Faculty of Medicine, King Khalid University, Saudi Arabia. He obtained his Post Doc. training in various Departments of Microbiology at the Universities of world repute in eight countries.

Professor Ahmad's research work mainly involved Multi resistant Eye Pathogens including Super Bugs MRSAs and their alternative treatment with newer antibacterial and innovative natural products especially the "Honey". Beside, many research projects having undertaken at various International Universities of world repute abroad, he successfully completed 5 projects at home.